No OS benefit to adding bendamustine to rituximab for marginal zone lymphoma
As a first-line treatment for patients with marginal zone lymphoma, the combination of bendamustine with rituximab (BR) conferred no advantage in overall survival
As a first-line treatment for patients with marginal zone lymphoma, the combination of bendamustine with rituximab (BR) conferred no advantage in overall survival
This issue of SOHO Insider features an article on US patient representation in global trials, an interview with Dr. Naval Daver, and photos
The US Food and Drug Administration has granted accelerated approval to sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell
SOHO invites delegates and attendees to submit an abstract for a poster or oral presentation during the Fourteenth Annual Meeting of the Society
In this interview from the AACR Annual Meeting 2026, Shuguang Leng, MBBS, PhD, an associate professor at the University of New Mexico Comprehensive
Meet Naval Daver, MD, a professor and director of the Leukemia Molecular Laboratory in the Department of Leukemia at the University of Texas
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College
Dr. Iftikhar is the SOHO Ambassador to Pakistan and a consultant clinical hematologist and hematopoietic stem cell transplantation physician at Armed Forces Bone
In vivo CAR-T therapy, which eliminates the complex manufacturing required for current ex vivo approaches, could represent the next generation of treatment, but
In this session from the SOHO Insider Community Oncology Brown Bag series, Dr. Krish Patel provides an overview on building partnerships between community